NovoCure (NVCR) Q2 2024 earnings summary

Executive summary

• Net revenues reached $150.4 million in Q2 2024, up 19% year-over-year, driven by a successful launch in France and improved U.S. approval rates.

• Achieved 3,963 active patients on therapy as of June 30, 2024, an 11% increase year-over-year, with growth in both U.S. and international markets.

• Positive Phase 3 METIS trial results in brain metastases from NSCLC were presented at ASCO 2024, supporting future regulatory submissions.

• Adjusted EBITDA turned positive at $1.1 million for Q2 2024, up from a loss of $27.2 million in Q2 2023, due to revenue growth and cost controls.

• Cash, cash equivalents, and short-term investments totaled $951.2 million at June 30, 2024, bolstered by a $100 million draw from a new credit facility.

Financial highlights

• Gross margin for Q2 2024 was 77%, up from 73% in Q2 2023.

• Net loss for Q2 2024 was $33.4 million, or $0.31 per share, narrowing from $57.4 million in Q2 2023.

• Operating expenses decreased 3% year-over-year to $149.3 million, with reductions in R&D, sales and marketing, and G&A.

• Financial income rose 24% to $10.9 million, driven by higher interest income and gains from debt redemption.

• $7.6–8 million in Q2 revenue was non-recurring, from prior period claims and a UK private payer.

Outlook and guidance

• FDA decision on NSCLC indication for Optune Lua expected in the second half of 2024; regulatory submissions also underway in Europe and Japan.

• Top-line data from the Phase 3 PANOVA-3 pancreatic cancer trial expected in Q4 2024.

• Company expects operating expenses to rise as it prepares for expansion into new indications, potentially outpacing gross profit.

• No further material improvement expected in U.S. net price; current levels are sustainable.